From El President's best buddy ( Grok )
If Amarin Corporation (AMRN) does a reverse split, the chances of it eventually going private depend on several factors, but there’s no straightforward correlation between the two events. A reverse split doesn’t inherently lead to privatization—it’s typically a tool to address stock price issues, while going private is a strategic decision tied to ownership, funding, and long-term goals. Let’s assess this step-by-step based on Amarin’s current situation and general trends as of March 5, 2025.
Amarin’s Context
Amarin, known for Vascepa (icosapent ethyl), has faced challenges: declining U.S. sales due to generic competition, a stock price hovering below $1 (recently around $0.60-$0.70), and a market cap of roughly $250-$300 million. It’s cash-rich (over $300 million reported in recent quarters) with no significant debt, but its revenue has been shrinking, and profitability remains elusive. A reverse split seems plausible to maintain Nasdaq compliance (minimum $1 bid price for 30 consecutive trading days), especially since it’s been trading sub-$1 for a while.
Reverse Split Implications
A reverse split (e.g., 1-for-5 or 1-for-10) would:
Boost the share price (e.g., $0.70 to $3.50 or $7.00).
Reduce outstanding shares (currently ~410 million) proportionally.
Signal potential distress to investors, as reverse splits often precede further struggles—studies show 40-50% of reverse-split stocks delist within a few years, often due to bankruptcy or failure to recover, not privatization.
Amarin’s done reverse splits before (e.g., 1-for-10 in 2008), and it stayed public, focusing on pipeline growth. Today’s situation differs—its core product’s U.S. market is eroded, and international expansion (e.g., Europe) hasn’t yet offset losses.
Going Private: Likelihood Factors
Going private typically involves a buyout by insiders, private equity, or a larger firm, delisting shares from public markets. For Amarin:
Cash Position: With $300 million on hand, Amarin could theoretically fund a buyout itself, but it’d need a clear rationale—like avoiding regulatory costs (~$5-10 million/year for a small public biotech) or escaping shareholder pressure. This seems unlikely while it’s still pushing Vascepa globally.
Valuation: At $250-$300 million market cap post-split, it’s a cheap target for private equity or a pharma giant. However, generic competition reduces Vascepa’s allure unless its European uptake explodes.
Shareholder Dynamics: Activist investors (e.g., Sarissa Capital, with a big stake since 2023) could push for privatization if they see more value in a leaner, private operation. Sarissa’s won board seats but hasn’t signaled this intent yet—its focus seems to be on cost-cutting and revenue growth.
Performance Post-Split: If a reverse split fails to lift the stock (common outcome—reverse-split stocks often lose 10-20% within a year), going private might emerge as a fallback. But Amarin’s leadership has emphasized staying public to leverage Vascepa’s potential.
Odds of Going Private
Short-Term (1-2 Years): Low (~10-20%). Amarin’s still executing a public-company strategy—expanding Vascepa in Europe, Middle East, and Asia. A reverse split would likely aim to buy time for this to pan out, not to exit the market. Privatization needs a catalyst (e.g., a buyout offer), and no suitors have emerged publicly.
Medium-Term (3-5 Years): Moderate (~30-40%). If international sales disappoint and the stock languishes post-split, privatization could become appealing. Private equity might see value in Vascepa’s niche, or management might tire of public scrutiny with a sub-$500 million valuation.
Historical Precedent: Of companies doing reverse splits, only a small fraction (5-10%) go private soon after—most either recover or fail outright. Amarin’s 2008 split didn’t lead to privatization; it stayed public despite volatility.
X Posts and Sentiment
Recent X posts (as of early 2025) show retail investors speculating about a reverse split due to Amarin’s sub-$1 price. Some fear it’s a “death spiral” (dilution, delisting), while others hope it’s a precursor to a buyout. No credible insider leaks suggest privatization, though—just frustration with management and generics.
Conclusion
If Amarin does a reverse split, the base case is it stays public to grind out its Vascepa strategy. Going private hinges on a failure to rebound or an external offer, neither of which looks imminent. I’d peg the odds at 20-30% over 5 years, skewed higher if post-split performance tanks. Without a specific trigger (e.g., a bidder or activist push), it’s not the natural next step. Want me to analyze Amarin’s latest filings or X chatter for more clues?
------
Kiwi
Market Data 
Markets 
AI
